The following video is part of today's MarketFoolery podcast, in which host Chris Hill, along with Charly Travers and Joe Magyer, discuss the latest business news. Shares of Human Genome Sciences doubled today after GlaxoSmithKline made a $2.6 billion bid for the biopharmaceutical company. In this segment, the guys analyze why Glaxo made the bid and why Human Genome Sciences passed it up. They also examine Human Genome Sciences' business to see whether the company just made a mistake walking away from $2.6 billion.
Full-time host of the Motley Fool Money radio show, MarketFoolery podcast, and other things. Part-time connoisseur of movies, basketball & fine bourbon.
- Apr 19, 2012 at 12:00AM